ArticleAntiviral research2018
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
Open access · hybridAbstract read
In one paragraph
Article in Antiviral research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- The use of maoto (Ma-Huang-Tang), a traditional Japanese Kampo medicine, to alleviate flu symptoms: a systematic review and meta-analysis.BMC complementary and alternative medicine · 2019Pooled it
- Triazavirin And Its Derivatives Act As Influenza A Virus Fusion Inhibitors.Pharmaceutical research · 2026Article
- A nanobody-based proteolysis-targeting chimera offers broad-spectrum protection against diverse influenza virus infections.Signal transduction and targeted therapy · 2026Article
- Oseltamivir aziridines are potent influenza neuraminidase inhibitors and imaging agents.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Influenza Virus Neuraminidase Glycoprotein, Its Inhibitors, and Their Resistance.Advances in experimental medicine and biology · 2026Review
- Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies.Influenza and other respiratory viruses · 2025Article
- Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.Antiviral research · 2025Article
- Article
- Molecular Evolution of Influenza A Viruses From Mauritius, 2017-2019.Influenza and other respiratory viruses · 2025Article
- Repurposing of the nucleoside analogs for influenza.Computational and structural biotechnology journal · 2025Article
- Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.Emerging microbes & infections · 2024Review
- R229I substitution from oseltamivir induction in HA1 region significantly increased the fitness of a H7N9 virus bearing NA 292K.Emerging microbes & infections · 2024Article
- Article
- Increase of Synergistic Secondary Antiviral Mutations in the Evolution of A(H1N1)pdm09 Influenza Virus Neuraminidases.Viruses · 2024Article
- Molecular Determinants of Drug Resistance and Mutation Patterns in Influenza Viruses Circulating in Poland Across Multiple Epidemic Seasons: Implications for Vaccination Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Genomic Analyses Uncover Evolutionary Features of Influenza A/H3N2 Viruses in Yunnan Province, China, from 2017 to 2022.Viruses · 2024Article
- Allopregnanolone targets nucleoprotein as a novel influenza virus inhibitor.Virologica Sinica · 2023Article
- Article
- Quinones as Promising Compounds against Respiratory Viruses: A Review.Molecules (Basel, Switzerland) · 2023Review
- Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018-2019 and 2019-2020 Influenza Seasons in Japan.Viruses · 2023Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 8 countries.
Angie LackenbyNational Infection Service, Public Health England, London, NW9 5HT, United Kingdom. Electronic address: angie.lackenby@phe.gov.uk.
Terry G BesselaarGlobal Influenza Programme, World Health Organization, Avenue Appia 20, 1211, Geneva 27, Switzerland.
Rod S DanielsThe Francis Crick Institute, Worldwide Influenza Centre (WIC), WHO Collaborating Centre for Reference and Research on Influenza, 1 Midland Road, London, NW1 1AT, United Kingdom.
Alicia FryWHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Centers for Diseases Control and Prevention (CDC), 1600 Clifton RD NE, MS-G16, Atlanta, GA, 30329, USA.
Vicki GregoryThe Francis Crick Institute, Worldwide Influenza Centre (WIC), WHO Collaborating Centre for Reference and Research on Influenza, 1 Midland Road, London, NW1 1AT, United Kingdom.
Larisa V GubarevaWHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Centers for Diseases Control and Prevention (CDC), 1600 Clifton RD NE, MS-G16, Atlanta, GA, 30329, USA.
Weijuan HuangWHO Collaborating Centre for Reference and Research on Influenza, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.
Aeron C HurtWHO Collaborating Centre for Reference and Research on Influenza, At the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, 3000, Australia; Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, 3010, Australia.
Sook-Kwan LeangWHO Collaborating Centre for Reference and Research on Influenza, At the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, 3000, Australia.
Raphael T C LeeBioinformatics Institute, Agency for Science, Technology and Research, 30 Biopolis Street, #07-01, Matrix, Singapore, 138671, Singapore.
Janice LoPublic Health Laboratory Centre, Centre for Health Protection, Department of Health, 382 Nam Cheong Street, Hong Kong, China.
Lori LollisWHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Centers for Diseases Control and Prevention (CDC), 1600 Clifton RD NE, MS-G16, Atlanta, GA, 30329, USA.
Sebastian Maurer-StrohBioinformatics Institute, Agency for Science, Technology and Research, 30 Biopolis Street, #07-01, Matrix, Singapore, 138671, Singapore; Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore, 117543, Singapore; National Public Health Laboratory, Ministry of Health, 3 Biopolis Drive, Synapse #05-14 to 16, Singapore, 138623, Singapore.
Takato OdagiriWHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.
Dmitriy PereyaslovDivision of Communicable Diseases, Health Security, & Environment, World Health Organization Regional Office for Europe, UN City, Marmorvej 51, DK-2100, Copenhagen Ø, Denmark.
Emi TakashitaWHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo, 208-0011, Japan.
Dayan WangWHO Collaborating Centre for Reference and Research on Influenza, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.
Wenqing ZhangGlobal Influenza Programme, World Health Organization, Avenue Appia 20, 1211, Geneva 27, Switzerland.
Adam MeijerNational Institute for Public Health and the Environment, PO Box 1, 3720 BA, Bilthoven, The Netherlands.
Agency for Science, Technology and Research · SGChinese Center For Disease Control and Prevention · CNNational Institute of Infectious Diseases · JPThe Francis Crick Institute · GBWorld Health Organization · CHDepartment of Health · CNNational Institute for Public Health and the Environment · NLPeter Doherty Institute · AUPublic Health England · GBThe University of Melbourne · AUWorld Health Organization Regional Office for Europe · DK
Funding
Cancer Research UK FC001030Medical Research Council FC001030Wellcome Trust FC001030
Abstract
A total of 13672 viruses, collected by World Health Organization recognised National Influenza Centres between May 2016 and May 2017, were assessed for neuraminidase inhibitor susceptibility by four WHO Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance Epidemiology and Control of Influenza. The 50% inhibitory concentration (IC
Indexed as
Drug Resistance, ViralAmino Acid SubstitutionAntiviral AgentsEnzyme InhibitorsGlobal HealthHumansInfluenza, HumanInhibitory Concentration 50Microbial Sensitivity TestsMutation, MissenseNeuraminidaseOrthomyxoviridaePrevalenceSequence Analysis, DNAAntiviral AgentsEnzyme InhibitorsNeuraminidaseInfluenzaInhibitorNeuraminidaseResistanceSurveillanceSusceptibility
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.